<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04167189</url>
  </required_header>
  <id_info>
    <org_study_id>2019-01A</org_study_id>
    <nct_id>NCT04167189</nct_id>
  </id_info>
  <brief_title>Assessing the Frequency of Lidocaine Ineffectiveness in ADHD</brief_title>
  <official_title>Prevalence of Lidocaine Ineffectiveness in the General Population Excluding Those With ADHD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PhenoSolve, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Boston Clinical Trials</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>PhenoSolve, LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This work will assess the prevalence in the ADHD of the ineffectiveness of the anesthetic
      Lidocaine.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Using a non-invasive, pain-free, taste-based approach to assess lidocaine effectiveness, the
      study will assess the frequency of ineffectiveness in the target population. This study will
      be compared with a similar assessment among the general population (NCT03676725). The
      controlled trial will assess the ability of lidocaine oral gel to block taste (e.g., sweet)
      in 40 adults, with a history of ADHD.
    </textblock>
  </detailed_description>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    Pandemic (Covid 19)
  </why_stopped>
  <start_date type="Actual">January 20, 2020</start_date>
  <completion_date type="Anticipated">March 30, 2021</completion_date>
  <primary_completion_date type="Actual">March 30, 2020</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>A group of 40 subjects will be assessed.</intervention_model_description>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>The scoring of the lidocaine test is masked, using the coded identity of the tastes. The tastes will be assessed in random order. The subjects and other study personnel will be told not to discuss what the subject could or couldn't taste. Scoring will not be shared with the testing site until all testing is complete.
This is one of the last studies with an IRB for each arm and site. Hence it appears to be a single arm, but the other arms are separately registered with ClinicalTrials.gov</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency of lidocaine ineffectiveness in ADHD</measure>
    <time_frame>1 day</time_frame>
    <description>Subjects will be asked to identify each taste and its intensity on a 0 (no taste) to 9 (very intense) scale.</description>
  </primary_outcome>
  <other_outcome>
    <measure>Comparison of frequency of lidocaine ineffectiveness in those in general population (NCT03676725)</measure>
    <time_frame>1 day</time_frame>
    <description>Subjects will be asked to identify each taste and its intensity on a 0 (no taste) to 9 (very intense) scale.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>ADHD</condition>
  <arm_group>
    <arm_group_label>ADHD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will be tested with lidocaine gel.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lidocaine gel</intervention_name>
    <description>Septodont 5% oral lidocaine gel (NDC 0362-0221-10), 75 mg premeasured by compounding pharmacy and dispensed into blister pack</description>
    <arm_group_label>ADHD</arm_group_label>
    <other_name>Intervention</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria: ADHD

        Exclusion Criteria for both arms:

          1. known adverse reactions to lidocaine

          2. epilepsy, IQ &lt;80, severe head trauma, birth weight &lt;2270 grams, and severe autism;

          3. treatment currently with potassium or potassium-elevating drugs such as
             renin-angiotensin-aldosterone blockers;

          4. generalized anxiety disorders (but dental-specific anxiety will not be an exclusion
             because many of these individuals may be ones with anxiety because of painful dental
             experiences with lidocaine ineffectiveness);

          5. mouth sores;

          6. Ehlers Danlos syndrome, and

          7. red hair.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>13 Years</minimum_age>
    <maximum_age>49 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Segal, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>PhenoSolve, LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Boston Clinical Trials</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.amazon.com/ADHD-Does-Not-Exist-Hyperactivity/dp/006226673X</url>
    <description>Saul R (2014) &quot;ADHD Does Not Exist&quot;. HarperCollins</description>
  </link>
  <link>
    <url>https://pdfs.semanticscholar.org/1778/f693dc7dd257ab98a96b5bf03408d9cef3eb.pdf</url>
    <description>Rozanski RJ, Primosch RE, Courts FJ (1988). Clinical efficacy of 1 and 2% solutions of lidocaine. Pediatr Dent.10:287-90</description>
  </link>
  <link>
    <url>https://www.uni-ulm.de/fileadmin/website_uni_ulm/med.inst.040/Dokumente/owner.html</url>
    <description>Segal MM, Jurkat-Rott K, Levitt J, Lehmann-Horn F (2014) Hypokalemic periodic paralysis - an owner's manual</description>
  </link>
  <link>
    <url>https://patents.google.com/patent/WO2017035470A1/en</url>
    <description>Segal MM (2015) Devices, Kits, and Methods for Determining Sensitivity to Anesthetics. US Patent Filing 62/210,747, Filed 09/14/2015</description>
  </link>
  <link>
    <url>https://clinicaltrials.gov/ct2/show/NCT03563573</url>
    <description>Companion study</description>
  </link>
  <results_reference>
    <citation>Infante MA, Moore EM, Nguyen TT, Fourligas N, Mattson SN, Riley EP. Objective assessment of ADHD core symptoms in children with heavy prenatal alcohol exposure. Physiol Behav. 2015 Sep 1;148:45-50. doi: 10.1016/j.physbeh.2014.10.014. Epub 2014 Oct 23.</citation>
    <PMID>25447751</PMID>
  </results_reference>
  <results_reference>
    <citation>Levitt JO. Practical aspects in the management of hypokalemic periodic paralysis. J Transl Med. 2008 Apr 21;6:18. doi: 10.1186/1479-5876-6-18. Erratum in: J Transl Med. 2014;12:198. Dosage error in article text.</citation>
    <PMID>18426576</PMID>
  </results_reference>
  <results_reference>
    <citation>Nakai Y, Milgrom P, Mancl L, Coldwell SE, Domoto PK, Ramsay DS. Effectiveness of local anesthesia in pediatric dental practice. J Am Dent Assoc. 2000 Dec;131(12):1699-705.</citation>
    <PMID>11143733</PMID>
  </results_reference>
  <results_reference>
    <citation>Segal MM. We cannot say whether attention deficit hyperactivity disorder exists, but we can find its molecular mechanisms. Pediatr Neurol. 2014 Jul;51(1):15-6. doi: 10.1016/j.pediatrneurol.2014.04.014. Epub 2014 Apr 18.</citation>
    <PMID>24938135</PMID>
  </results_reference>
  <results_reference>
    <citation>Segal MM, Rogers GF, Needleman HL, Chapman CA. Hypokalemic sensory overstimulation. J Child Neurol. 2007 Dec;22(12):1408-10. doi: 10.1177/0883073807307095.</citation>
    <PMID>18174562</PMID>
  </results_reference>
  <results_reference>
    <citation>Segal MM, Douglas AF. Late sodium channel openings underlying epileptiform activity are preferentially diminished by the anticonvulsant phenytoin. J Neurophysiol. 1997 Jun;77(6):3021-34.</citation>
    <PMID>9212254</PMID>
  </results_reference>
  <results_reference>
    <citation>Teicher MH, Polcari A, Fourligas N, Vitaliano G, Navalta CP. Hyperactivity persists in male and female adults with ADHD and remains a highly discriminative feature of the disorder: a case-control study. BMC Psychiatry. 2012 Nov 7;12:190. doi: 10.1186/1471-244X-12-190.</citation>
    <PMID>23134619</PMID>
  </results_reference>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>November 12, 2019</study_first_submitted>
  <study_first_submitted_qc>November 15, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 18, 2019</study_first_posted>
  <last_update_submitted>July 14, 2020</last_update_submitted>
  <last_update_submitted_qc>July 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 15, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lidocaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The investigators plan to submit for publication descriptions of what was accomplished, and the evaluations as described in the study, including the incidence of lidocaine ineffectiveness in those with ADHD and in the general population.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>3 months</ipd_time_frame>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

